We found moderate upregulation of CTL4 expression in cases with progressive disease at baseline; however, recently, the findings of Klumper et al. [37] indicated that reduced methylation of the CTLA4 promoter, linked to elevated mRNA levels, predicts a positive response to immune checkpoint blockade and favorable outcomes among ccRCC patients. Here, SLC44A4 is linked to nonpapillary renal cell carcinoma.